docetaxel

Open Access
Oral-recombinant Methioninase Converts an Osteosarcoma from Docetaxel-resistant to -Sensitive in a Clinically-relevant Patient-derived Orthotopic-xenograft (PDOX) Mouse Model
YUSUKE AOKI, YASUNORI TOME, NATHANIEL F. WU, JUN YAMAMOTO, KAZUYUKI HAMADA, QINGHONG HAN, MICHAEL BOUVET, KOTARO NISHIDA and ROBERT M. HOFFMAN

Anticancer Research April 2021, 41 (4) 1745-1751; DOI: https://doi.org/10.21873/anticanres.14939
Open Access
Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
MOTOYUKI SUZUKI, YUKINORI TAKENAKA, TOSHIHIRO KISHIKAWA, YOSHIFUMI YAMAMOTO, ATSUSHI HANAMOTO, YOICHIRO TOMIYAMA, TAKAHITO FUKUSUMI, TAKAHIRO MICHIBA, NORIHIKO TAKEMOTO, SUSUMU NAKAHARA and HIDENORI INOHARA

Anticancer Research April 2021, 41 (4) 2045-2051; DOI: https://doi.org/10.21873/anticanres.14973
You have access
Hyperthermia During Intraperitoneal Chemotherapy With Paclitaxel or Docetaxel for Ovarian Cancer: Is There Any Benefit?
EELCO DE BREE, DESPOINA KATSOUGKRI, HARA POLIOUDAKI, ELENA TSANGARIDOU, DIMOSTHENIS MICHELAKIS, ODYSSEAS ZORAS and PANAYIOTIS THEODOROPOULOS

Anticancer Research December 2020, 40 (12) 6769-6780; DOI: https://doi.org/10.21873/anticanres.14700
You have access
Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer
YUSUKE SHIMURA, YUKIO SUGA, SHINGO ITAI, HIROAKI IWAMOTO, YUTA TAKEZAWA, HIROSHI YAEGASHI, KOUJI IZUMI, TSUTOMU SHIMADA, YOSHIMICHI SAI, RYO MATSUSHITA and ATSUSHI MIZOKAMI

Anticancer Research August 2020, 40 (8) 4291-4297; DOI: https://doi.org/10.21873/anticanres.14431
You have access
Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX
JEAN-DAVID FUMET, JULIE VINCENT, LEILA BENGRINE, AUDREY HENNEQUIN, LAURA GRANCONATO, REMI PALMIER and FRANÇOIS GHIRINGHELLI

Anticancer Research July 2020, 40 (7) 4011-4015; DOI: https://doi.org/10.21873/anticanres.14395
You have access
Phase II Study of Docetaxel, Cisplatin, and 5-Fluorouracil Chemoradiotherapy for Unresectable Esophageal Cancer
KOSUKE TAKAHASHI, YOSHIAKI OSAKA, YOSHIHIRO OTA, TAKAFUMI WATANABE, KENICHI IWASAKI, SHINGO TACHIBANA, YUICHI NAGAKAWA, KENJI KATSUMATA and AKIHIKO TSUCHIDA

Anticancer Research May 2020, 40 (5) 2827-2832; DOI: https://doi.org/10.21873/anticanres.14256
You have access
Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel
MASAKI SHIOTA, MOTONOBU NAKAMURA, AKIRA YOKOMIZO, TOSHIHISA TOMODA, NAOTAKA SAKAMOTO, NARIHITO SEKI, SHUJI HASEGAWA, TAKAKAZU YUNOKI, MASAHIKO HARANO, KENTARO KUROIWA and MASATOSHI ETO

Anticancer Research January 2020, 40 (1) 335-339; DOI: https://doi.org/10.21873/anticanres.13957
You have access
ANO7 rs77559646 Is Associated With First-line Docetaxel Treatment Response in Metastatic Castration-resistant Prostate Cancer
ELINA KAIKKONEN, OTTO ETTALA, ILKKA NIKULAINEN, PEKKA TAIMEN, ILARI LEHTINEN, PETER J. BOSTRÖM, PIRKKO-LIISA KELLOKUMPU-LEHTINEN and JOHANNA SCHLEUTKER

Anticancer Research October 2019, 39 (10) 5353-5359; DOI: https://doi.org/10.21873/anticanres.13728
You have access
Low-dose Docetaxel Enhanced the Anticancer Effect of Temsirolimus by Overcoming Autophagy in Prostate Cancer Cells
SO INAMURA, HIDEAKI ITO, MINEKATSU TAGA, KATSUKI TSUCHIYAMA, HITOMI HOSHINO, MOTOHIRO KOBAYASHI and OSAMU YOKOYAMA

Anticancer Research October 2019, 39 (10) 5417-5425; DOI: https://doi.org/10.21873/anticanres.13735
You have access
Blockade of γ-Glutamylcyclotransferase Enhances Docetaxel Growth Inhibition of Prostate Cancer Cells
HIROKO TAKAGI, HIROMI II, SUSUMU KAGEYAMA, EIKI HANADA, KEIKO TANIGUCHI, TAKU YOSHIYA, TOKUHIRO CHANO, AKIHIRO KAWAUCHI and SUSUMU NAKATA

Anticancer Research September 2019, 39 (9) 4811-4816; DOI: https://doi.org/10.21873/anticanres.13666

Main menu

User menu

Search

docetaxel

Pages